ASHP guidelines on handling hazardous drugs

American Journal of Health-System Pharmacy

Volumn 63, Issue 12, 2006, Pages 1172-1191

[No Author Info available]

Author keywords

American Society of Health System Pharmacists; Antineoplastic agents; Contamination; Control, quality; Equipment; Guidelines; Health professions; Toxicity, environmental

Indexed keywords

ASEPSIS; COMPETENCE; DRUG CONTAMINATION; DRUG LABELING; DRUG MANUFACTURE; DRUG PACKAGING; DRUG SAFETY; HAZARDOUS WASTE; MATERIALS HANDLING; MEDICAL DECISION MAKING; PATIENT SAFETY; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTECTIVE EQUIPMENT; REVIEW; STANDARD; WASTE DISPOSAL;

EID: 33746612399     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050529     Document Type: Review

References (115)

1. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033-49.
2. Controlling occupational exposure to hazardous drugs. Chapter 21. In: OSHA technical manual (OSHA Instruction CPL 2-2.20B CH-4). Washington, DC: Directorate of Technical Support, Occupational Safety and Health Administration; 1995.
3. Occupational Safety and Health Administration. Controlling occupational exposure to hazardous drugs. OSHA technical manual, TED 1-0.15A. Section VI. Chapter 2. www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html (accessed 2005 Feb 15).
4. National Institute for Occupational Safety and Health. NIOSH alert: preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. www.cdc.gov/niosh/docs/2004-165/ (accessed 2006 Mar 14).
5. Harrison BR. Risks of handling cytotoxic drugs. In: Perry MC, ed. The chemotherapy source book. 3rd ed. Philadelphia: Lippincott, Williams and Wilkins; 2001:566-82.
6. Baker ES, Connor TH. Monitoring occupational exposure to cancer chemotherapy drugs. Am J Health-Syst Pharm. 1996; 53:2713-23.
7. Sessink PJ, Bos RP. Drugs hazardous to healthcare workers: evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Saf. 1999; 20:347-59.
8. Harris CC. The carcinogenicity of anticancer drugs: a hazard in man. Cancer. 1976; 37:1014-23.
9. Falck K, Grohn P, Sorsa M et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet. 1979; 1:1250-1. Letter.
10. Ladik CF, Stoehr GP, Maurer MA. Precautionary measures in the preparation of antineoplastics. Am J Hosp Pharm. 1980; 37:1184, 1186.
11. Crudi CB. A compounding dilemma: I've kept the drug sterile but have I contaminated myself? NITA. 1980; 3:77-8.
12. Crudi CB, Stephens BL, Maier P. Possible occupational hazards associated with the preparation/administration of anti-neoplastic agents. NITA. 1982; 5:264-6.
13. Reynolds RD, Ignoffo R, Lawrence J et al. Adverse reactions to AMSA in medical personnel. Cancer Treat Rep. 1982; 66:1885. Letter.
14. Knowles RS, Virden JE. Handling of injectable antineoplastic agents. Br Med J. 1980; 281:589-91.
15. McFarlane A. Ophthalmic problems in staff handling cytotoxic drugs. Aust J Hosp Pharm. 1986; 16:145. Letter.
16. Curran CF, Luce JK. Ocular adverse reactions associated with adriamycin (doxorubicin). Am J Ophthalmol. 1989; 108:709-11.
17. McLendon BF, Bron AJ. Corneal toxicity from vinblastine solution. Br J Ophthalmol. 1978; 62:97-9.
18. Valanis BG, Hertzberg V, Shortridge L. Antineoplastic drugs: handle with care. AAOHN J. 1987; 35:487-92.
19. Valanis BG, Vollmer WM, Labuhn KT et al. Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993; 50:455-62.
20. Hemminki K, Kyyronen P, Lindholm ML. Spontaneous abortions and malformations in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards, based on registered information of outcome. J Epidemiol Community Health. 1985; 39:141-7.
21. Selevan SG, Lindbohm ML, Hornung RW et al. A study of occupational exposure to antineoplastic drugs and fetal loss in nurses. N Engl J Med. 1985; 313:1173-8.
22. Valanis BG, Vollmer WM, Labuhn KT et al. Occupational exposure to antineoplastic agents and self-reported infertility among nurses and pharmacists. J Occup Environ Med. 1997; 39:574-80.
23. Valanis BG, Vollmer WM, Steele P. Occupational exposure to antineoplastic agents: self-reported miscarriages and stillbirths among nurses and pharmacists. J Occup Environ Med. 1999; 41:632-8.
24. National Toxicology Program. Report on carcinogens, 11th ed. http://ehis. niehs.nih.gov/roc/toc9.html (accessed 2005 Sep 15).
25. International Agency for Research on Cancer. Monographs database on carcinogenic risks to humans. www-cie. iarc.fr/ (accessed 2004 Nov 1).
26. Skov T, Lynge E, Maarup B et al. Risks for physicians handling antineoplastic drugs. Lancet. 1990; 336:1446. Letter.
27. Skov T, Maarup B, Olsen J et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med. 1992; 49:855-61.
28. Sessink PJ, Kroese ED, van Kranen HJ et al. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health. 1995; 67:317-23.
29. Connor TH, Anderson RW, Sessink PJ et al. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. Am J Health-Syst Pharm. 1999; 56:1427-32.
30. Sessink PJ, Boer KA, Scheefhals AP et al. Occupational exposure to antineoplastic agents at several departments in a hospital: environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992; 64:105-12.
31. Sessink PJ, Van de Kerkhof MC, Anzion RB et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route? Arch Environ Health. 1994; 49:165-9.
32. Sessink PJ, Wittenhorst BC, Anzion RB et al. Exposure of pharmacy technicians to antineoplastic agents: reevaluation after additional protective measures. Arch Environ Health. 1997; 52:240-4.
33. Ensslin AS, Stoll Y, Pethran A et al. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup Environ Med. 1994; 51:229-33.
34. Wick C, Slawson MH, Jorgenson JA et al. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents. Am J Health-Syst Pharm. 2003; 60:2314-20.
35. Schmaus G, Schierl R, Funck S. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health-Syst Pharm. 2002; 59:956-61.
36. Hirst M, Tse S, Mills DG et al. Occupational exposure to cyclophosphamide. Lancet. 1984; 1:186-8.
37. Ensslin AS, Pethran A, Schierl R et al. Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs. Int Arch Occup Environ Health. 1994; 65:339-42.
38. Ensslin AS, Huber R, Pethran A et al. Biological monitoring of hospital pharmacy personnel occupationally exposed to cytostatic drugs: urinary excretion and cytogenetics studies. Int Arch Occup Environ Health. 1997; 70:205-8.
39. Minoia C, Turci R, Sottani C et al. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun Mass Spectrom. 1998; 12:1485-93.
40. Nygren O, Lundgren C. Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int Arch Occup Environ Health. 1997; 70:209-14.
41. Pethran A, Schierl R, Hauff K et al. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003; 76:5-10.
42. Larson RR, Khazaeli MB, Dillon HK. A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl Occup Environ Hyg. 2003; 18:120-31.
43. Opiolka S, Schmidt KG, Kiffmeyer K et al. Determination of the vapor pressure of cytotoxic drugs and its effects on occupational safety. J Oncol Pharm Practice. 2000; 6:15. Abstract.
44. Kiffmeyer TK, Kube C, Opiolka S et al. Vapor pressures, evaporation behavior and airborne concentrations of hazardous drugs: implications for occupational safety. Pharm J. 2002; 268:331-7.
45. Connor TH, Shults M, Fraser MP. Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 36 °C using a dessicator technique. Mutat Res. 2000; 470:85-92.
46. Kromhout H, Hoek F, Uitterhoeve R et al. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg. 2000; 44:551-60.
47. Dorr RT, Alberts DS. Topical absorption and inactivation of cytotoxic anticancer agents in vitro. Cancer. 1992; 70(4 suppl):983-7.
48. Bos RP, Leenaars AO, Theuws JL et al. Mutagenicity of urine from nurses handling cytostatic drugs, influence of smoking. Int Arch Occup Environ Health. 1982; 50:359-69.
49. Evelo CT, Bos RP, Peters JG et al. Urinary cyclophosphamide assay as a method for biological monitoring of occupational exposure to cyclophosphamide. Int Arch Occup Environ Health. 1986; 58:151-5.
50. Pharmaceutical compounding-sterile preparations (general information chapter 797). In: The United States pharmacopeia, 28th rev., and The national formulary, 23rd ed. Rockville, MD: United States Pharmacopeial Convention; 2004:2461-77.
51. Standard 14644-1. Cleanrooms and associated environments - part 1: classification of air cleanliness. 1st ed. Geneva, Switzerland: International Organization for Standardization; 1999.
52. 29 C.F.R. 1910-1200.
53. Occupational Safety and Health Administration. Hazard communication standard: hazard communication-final rule. 29 C.F.R. 1910. Fed Regist. 1987; 52:31852-86.
54. Kiffmeyer TK, Ing KG, Schoppe G. External contamination of cytotoxic drug packing: safe handling and cleaning procedures. J Oncol Pharm Pract. 2000; 6:13.
55. Connor TH, Sessink PJ, Harrison BR et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health-Syst Pharm. 2005; 62:475-84.
56. 29 C.F.R. 1910.134.
57. National Institute for Occupational Safety and Health. Summary for respirator users. www.cdc.gov/niosh/respsumm.html (accessed 2005 Sep 15).
58. Nguyen TV, Theiss JC, Matney TS. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res. 1982; 42:4792-6.
59. Anderson RW, Puckett WH Jr, Dana WJ et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm. 1982; 39:1881-7.
60. Rubino FM, Floridia L, Pietropaolo AM et al. Measurement of surface contamination by certain antineoplastic drugs using high-performance liquid chromatography: applications in occupational hygiene investigations in hospital environments. Med Lav. 1999; 90:572-83.
61. Sessink PJ, Anzion RB, Van den Broeck PH et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 1992; 14:16-22.
62. NSF/ANSI standard 49-04: class II (laminar flow) biosafety cabinetry. Ann Arbor, MI: NSF International; 2004.
63. Clark RP, Goff MR. The potassium iodide method for determining protection factors in open-fronted microbiological safety cabinets. J Appl Bacteriol. 1981; 51:439-60.
64. National Sanitation Foundation standard 49: Class II (laminar flow) biohazard cabinetry. Ann Arbor, MI: National Sanitation Foundation; 1987.
65. American Glovebox Society. Guidelines for gloveboxes. 2nd ed. Santa Rosa, CA: AGS; AGS-G001-1998.
66. General Services Administration. Federal standard 209e: clean room and work station requirements, controlled environments. Washington, DC: U.S. Government Printing Office; 1992.
67. Food and Drug Administration. Guidance for industry-sterile drug products produced by aseptic processing. Current good manufacturing practice. www. fda.gov/cder/guidance/5882fnl.pdf (accessed 2005 Sep 10).
68. Tillett L. Barrier isolators as an alternative to a cleanroom. Am J Health-Syst Pharm. 1999; 56:1433-6.
69. Mosko P, Rahe H. Barrier isolation technology: a labor-efficient alternative to cleanrooms. Hosp Pharm. 1999; 34:834-8.
70. Rahe H. Understanding the critical components of a successful cleanroom and barrier isolator project. Am J Health-Syst Pharm. 2000; 57:346-50.
71. Controlled Environment Testing Association. CETA applications guide for the use of barrier isolators in compounding sterile preparations in healthcare facilities. www.cetainternational. org/reference/isolator3.pdf (accessed 2005 Sep 10).
72. Mason HJ, Blair S, Sams C et al. Exposure to antineoplastic drugs in two UK hospital pharmacy units. Ann Occup Hyg. 2005; 49:603-10.
73. Nygren O, Gustavsson B, Strom L et al. Exposure to anti-cancer drugs during preparation and administration. Investigations of an open and a closed system. J Environ Monit. 2002; 4:739-42.
74. Sessink PJ, Rolf ME, Ryden NS. Evaluation of the PhaSeal hazardous drug containment system. Hosp Pharm. 1999; 34:1311-7.
75. Sessink PJ. How to work safely outside the biological safety cabinet. J Oncol Pharm Pract. 2000; 6:15. Abstract.
76. Connor TH, Anderson RW, Sessink PJ et al. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area. Am J Health-Syst Pharm. 2002; 59:68-72.
77. Vandenbroucke J, Robays H. How to protect environment and employees against cytotoxic agents: the UZ Gent experience. J Oncol Pharm Pract. 2001; 6:146-52.
78. Spivey S, Connor TH. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm. 2003; 38:135-9.
79. Hoy RH, Stump LM. Effect of an air-venting filter device on aerosol production from vials. Am J Hosp Pharm. 1984; 41:324-6.
80. Connor TH. Permeability testing of glove materials for use with cancer chemotherapy drugs. Oncology. 1995; 52:256-9.
81. Singleton LC, Connor TH. An evaluation of the permeability of chemotherapy gloves to three cancer chemotherapy drugs. Oncol Nurs Forum. 1999; 26:1491-6.
82. Gross E, Groce DF. An evaluation of nitrile gloves as an alternative to natural rubber latex for handling chemotherapeutic agents. J Oncol Pharm Pract. 1998; 4:165-8.
83. Connor TH. Permeability of nitrile rubber, latex, polyurethane, and neoprene gloves to 18 antineoplastic drugs. Am J Health-Syst Pharm. 1999; 56:2450-3.
84. Klein M, Lambov N, Samev N et al. Permeation of cytotoxic formulations through swatches from selected medical gloves. Am J Health-Syst Pharm. 2003; 60:1006-11.
85. American Society for Testing and Materials D 6978-05 standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs. West Conshohocken, PA: American Society for Testing and Materials; 2005.
86. Connor TH, Xiang Q. The effect of isopropyl alcohol on the permeation of gloves exposed to antineoplastic agents. J Oncol Pharm Pract. 2000; 6:109-14.
87. Colligan SA, Horstman SW. Permeation of cancer chemotherapeutic drugs through glove materials under static and flexed conditions. Appl Occup Environ Hyg. 1990; 5:848-52.
88. Sessink PJ, Cerna M, Rossner P et al. Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutat Res. 1994; 309:193-9.
89. National Institutes of Health. Recommendations for the safe handling of cytotoxic drugs. www.nih.gov/od/ors/ds/pubs/cyto/index.htm (accessed 2004 Nov 1).
90. Polovich M, White JM, Kelleher LO, eds. Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. Pittsburgh: Oncology Nursing Society; 2005.
91. Connor TH. An evaluation of the permeability of disposable polypropylene-based protective gowns to a battery of cancer chemotherapy drugs. Appl Occup Environ Hyg. 1993; 8:785-9.
92. Harrison BR, Kloos MD. Penetration and splash protection of six disposable gown materials against fifteen antineoplastic drugs. J Oncol Pharm Pract. 1999; 5:61-6.
93. Laidlaw JL, Connor TH, Theiss JC et al. Permeability of four disposal protective-clothing materials to seven antineoplastic drugs. Am J Hosp Pharm. 1985; 42:2449-54.
94. Valanis B, Shortridge L. Self protective practices of nurses handling antineoplastic drugs. Oncol Nurs Forum. 1987; 14:23-7.
95. Labuhn K, Valanis B, Schoeny R et al. Nurses' and pharmacists' exposure to antineoplastic drugs: findings from industrial hygiene scans and urine mutagenicity tests. Cancer Nurs. 1998; 21:79-89.
96. NuAire. Containment capabilities of a Class II, type A2 BSC using a chemo pad on the worksurface. Technical bulletin. www.nuaire.com/tech_papers/ Containment_Capabilities_using_Chemo_ Pad.PDF (accessed 2006 Mar 23).
97. Farris J. Barrier isolators and the reduction of contamination in preparation of parenteral products. www.mic4.com/articles/parenteral-products. php (accessed 2006 Mar 23).
98. Wilson JP, Solimando DA. Aseptic technique as a safety precaution in the preparation of antineoplastic agents. Hosp Pharm. 1981; 15:575-81.
99. Harrison BR, Godefroid RJ, Kavanaugh EA. Quality-assurance testing of staff pharmacists handling cytotoxic agents. Am J Health-Syst Pharm. 1996; 53:402-7.
100. Shahsavarani S, Godefroid RJ, Harrison BR. Evaluation of occupational exposure to tablet trituration dust. Paper presented at ASHP Midyear Clinical Meeting. Atlanta, GA; 1993 Dec 6.
101. Johnson EG, Janosik JE. Manufacturers' recommendations for handling spilled antineoplastic agents. Am J Hosp Pharm. 1989; 46:318-9.
102. Benvenuto JA, Connor TH, Monteith DK et al. Degradation and inactivation of antitumor drugs. J Pharm Sci. 1993; 82:988-91.
103. Hansel S, Castegnaro M, Sportouch MH et al. Chemical degradation of wastes of antineoplastic agents: cyclophosphamide, ifosfamide, and melphalan. Int Arch Occup Environ Health. 1997;69:109-14.
104. Polovich M, Belcher C, Glynn-Tucker EM et al. Safe handling of hazardous drugs. Pittsburgh: Oncology Nursing Society; 2003.
105. 40 C.F.R. 261.33.
106. Resource Conservation and Recovery Act of 1976. 42 U.S.C. 82 §6901-92.
107. 40 C.F.R. 261.20-24C.
108. 40 C.F.R. 261.3.38D.
109. 40 C.F.R. 261.7.
110. Vaccari PL, Tonat K, DeChristoforo R et al. Disposal of antineoplastic wastes at the National Institutes of Health. Am J Hosp Pharm. 1984; 41:87-93.
111. 40 C.F.R. 261.7(b)(1)-(3).
112. 49 C.F.R. 172.0-.123,173,178,179.
113. 29 C.F.R. 1910.120(e)(3)(i).
114. 29 C.F.R. 1910.120(q)(1-6).
115. 40 C.F.R. 260-8,270.